Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

874
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
874
Obesity01:24

Obesity

1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

274
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
274
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

363
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
363
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

334
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
334
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

306
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
306

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Position Statement on Autonomous Adrenaline Administration for Anaphylaxis by Nursing Professionals in Spain: Joint Recommendations From the Anaphylaxis and Nursing Committees of the Spanish Society of Allergy and Clinical Immunology (SEAIC).

Journal of investigational allergology & clinical immunology·2025
Same author

A predictive model of non-diabetic kidney disease in patients with diabetes mellitus and chronic kidney disease. A Spanish multi-center study.

Nefrologia·2025
Same author

Serum PFAS and lipid concentrations in Ecuadorian adolescents.

Archives of environmental & occupational health·2025
Same author

[Practical Guidance on the Detection of NTRK Fusions in Sarcomas: Current Status and Diagnostic Challenges].

Acta medica portuguesa·2025
Same author

Corrigendum to "Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia" [<i>Kidney International Reports</i> Volume 9, Issue 5, May 2024, Pages 1419-1428].

Kidney international reports·2025
Same author

Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia.

Kidney international reports·2024

Related Experiment Video

Updated: Mar 21, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.6K

Low Insulin-Like Growth Factor-1 Level in Obesity Nephropathy: A New Risk Factor?

Ioana Bancu1,2, Maruja Navarro Díaz1,3, Assumpta Serra1,3

  • 1Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

Plos One
|May 4, 2016
PubMed
Summary

Low insulin-like growth factor-1 (IGF-1) serum levels are linked to kidney damage in morbidly obese individuals. This finding highlights IGF-1 as a potential risk factor for obesity-related renal injury, even without apparent clinical symptoms.

More Related Videos

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
08:34

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis

Published on: June 3, 2016

15.9K
A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.2K

Related Experiment Videos

Last Updated: Mar 21, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.6K
Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
08:34

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis

Published on: June 3, 2016

15.9K
A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.2K

Area of Science:

  • Nephrology
  • Endocrinology
  • Obesity Medicine

Background:

  • Insulin-like growth factor-1 (IGF-1) plays a role in kidney function, influencing blood flow and filtration.
  • Obesity is a known risk factor for chronic kidney disease and associated glomerular lesions.
  • Limited human studies exist on IGF-1's role in obesity-related kidney injury.

Purpose of the Study:

  • To measure serum IGF-1 concentrations in morbidly obese patients with early, obesity-related glomerular lesions.
  • To investigate the association between IGF-1 levels and the presence of these renal lesions.

Main Methods:

  • Serum IGF-1 and IGF-1 standard deviation score (SDS-IGF-1) were analyzed in 80 morbidly obese patients undergoing renal biopsy.
  • Patients were categorized based on the presence and type of glomerular lesions.
  • Logistic regression was used to identify predictors of glomerular injury.

Main Results:

  • Significant differences in IGF-1 and SDS-IGF-1 levels were observed between patients with and without glomerular lesions.
  • Low SDS-IGF-1 levels were identified as a significant risk factor for kidney injury in multivariate analysis.
  • Specific lesion types showed varying IGF-1 levels, with glomerulomegaly, podocyte hypertrophy, and increased mesangial matrix/proliferation associated with lower IGF-1.

Conclusions:

  • Low serum IGF-1 levels are associated with renal lesions in morbidly obese patients.
  • SDS-IGF-1 is a potential biomarker for detecting early kidney injury in this population.
  • Further research is warranted to explore therapeutic interventions targeting IGF-1 in obesity-related nephropathy.